Can I Take Saw Palmetto with Cytomel (Liothyronine)?

What Is Cytomel (Liothyronine) and Who Takes It?

Liothyronine is the synthetic form of triiodothyronine (T3), the biologically active thyroid hormone that acts on nearly every cell in the body. Cytomel is the most widely prescribed brand in the United States. Prescribers use it either as monotherapy or alongside levothyroxine (T4) when patients remain symptomatic despite T4-only treatment.

The 2012 Bianco et al. Review in the Journal of Clinical Endocrinology and Metabolism documented that roughly 8 to 10 percent of patients on levothyroxine monotherapy still report hypothyroid symptoms, which is one reason combination T3 therapy continues to be studied and prescribed off-label in select cases. [1]

How Liothyronine Works

T3 binds thyroid hormone receptors (THR-alpha and THR-beta) in the nucleus, directly regulating gene transcription. Its half-life is approximately 2.5 days, compared to 7 days for T4, which means TSH and free T3 levels can shift more quickly when doses change. Clinicians typically dose liothyronine at 5 to 25 mcg once or twice daily, adjusting every 4 to 6 weeks based on labs and symptoms. [2]

Common Patient Profiles

Patients who receive liothyronine prescriptions frequently include those with confirmed hypothyroidism not controlled by levothyroxine alone, individuals who have undergone thyroidectomy, and some patients in hormone-optimization programs who add T3 to address fatigue, cognitive symptoms, or metabolic rate concerns. Men in testosterone-replacement programs are one growing subgroup, and those men may simultaneously consider saw palmetto for benign prostatic hyperplasia (BPH) or hair retention. That overlap is where the clinical question becomes practical.

What Is Saw Palmetto and Why Do People Take It?

Saw palmetto (Serenoa repens) is a small palm native to the southeastern United States. Its berry extract is one of the most purchased herbal supplements globally, with U.S. Sales exceeding $130 million annually according to the American Botanical Council 2022 market report.

Its two primary uses are reduction of BPH-related lower urinary tract symptoms and off-label use to slow androgenetic alopecia. A 2012 Cochrane review (32 trials, N=5,666) found saw palmetto produced modest but inconsistent improvements in urinary flow compared to placebo, though it did not reach statistical significance versus finasteride in head-to-head data. [3]

Mechanism of Action: 5-Alpha Reductase Inhibition

Saw palmetto's main pharmacological action is inhibition of 5-alpha reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). This is the same enzyme targeted by pharmaceutical 5-AR inhibitors finasteride and dutasteride. The inhibition is non-selective, affecting both type 1 and type 2 isoforms, though with substantially weaker potency than finasteride. [4]

Secondary Mechanisms Relevant to Thyroid Patients

Beyond 5-AR inhibition, saw palmetto has demonstrated in vitro inhibition of platelet aggregation, mild anti-inflammatory activity via cyclooxygenase (COX) pathways, and possible weak estrogenic activity at high concentrations. Each of these secondary mechanisms has theoretical relevance to a patient on thyroid hormone replacement.

Is There a Direct Drug Interaction Between Saw Palmetto and Liothyronine?

No confirmed pharmacokinetic interaction has been published in peer-reviewed literature as of early 2025. The two compounds do not share the same hepatic metabolic enzymes in a way that would predictably raise or lower blood concentrations of either.

Liothyronine is metabolized primarily by deiodination in peripheral tissues (liver, kidney, muscle) and by glucuronidation and sulfation in the liver. Saw palmetto does not appear to meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2D6, or CYP3A4 at typical therapeutic doses, based on a 2012 pharmacokinetic study by Markowitz et al. Examining Serenoa repens and cytochrome P450 activity. [5]

What the Interaction Really Is: Pharmacodynamic Overlap

The interaction is pharmacodynamic, meaning it arises from overlapping physiological effects rather than altered drug concentrations.

Three mechanisms are worth understanding:

1. Androgen-Thyroid Crosstalk

Thyroid hormones and androgens interact at the level of gene expression and cellular metabolism. T3 upregulates androgen receptor sensitivity in certain tissues, including the prostate. Simultaneously reducing DHT production with saw palmetto while elevating T3 with liothyronine could theoretically produce an unpredictable net effect on androgen-dependent tissues. This is largely theoretical; no clinical trial has quantified the magnitude. [6]

2. Mild Anticoagulant Risk

Saw palmetto inhibits thromboxane-B2-dependent platelet aggregation. Hyperthyroid states and, to a lesser extent, supraphysiologic T3 levels, are independently associated with increased cardiovascular sensitivity, including mild effects on coagulation. A 2011 case series in the Journal of the American Board of Family Medicine documented saw palmetto-associated bleeding complications in three patients, two of whom were on concurrent medications affecting coagulation. [7]

If a patient's liothyronine dose is not yet optimized and they are running high-normal or mildly supraphysiologic free T3, adding saw palmetto's antiplatelet activity creates a small but non-zero additive risk. The risk remains low in absolute terms for most healthy adults.

3. Potential Interference with Thyroid Hormone Absorption

Saw palmetto is a fat-soluble extract, typically taken with food and oils. It does not chelate thyroid hormone the way calcium, iron, or high-fiber supplements do. There is no mechanistic reason to expect saw palmetto to directly reduce liothyronine absorption, and no study has shown it does. Still, the practical standard of separating all supplements from liothyronine by at least 4 hours is reasonable and adds no meaningful burden.

Clinical Risk Stratification: Who Should Be More Careful?

Not every patient on liothyronine and saw palmetto faces the same risk profile. Understanding where on the risk spectrum a given patient sits helps guide the conversation.

Lower-Risk Patients

A man with well-controlled hypothyroidism, stable TSH between 0.5 and 2.5 mIU/L, no cardiac history, no concurrent anticoagulants, and no planned surgery in the next month represents a low-risk scenario. Taking saw palmetto 160 mg twice daily (the standard studied dose) alongside a stable liothyronine regimen is unlikely to produce measurable harm, provided labs are monitored at the next scheduled interval.

Moderate-Risk Patients

Patients with atrial fibrillation, a history of bleeding events, or those on aspirin, NSAIDs, or fish oil in addition to liothyronine occupy a moderate-risk tier. The additive antiplatelet burden from saw palmetto should be discussed explicitly with a prescriber. Dose reduction of saw palmetto or substitution with a pharmaceutical 5-AR inhibitor (finasteride 1 mg daily for hair or 5 mg daily for BPH) may be appropriate.

Higher-Risk Patients

Patients scheduled for surgery, those with poorly controlled thyroid status (free T3 outside reference range), or individuals on warfarin, apixaban, or other anticoagulants should avoid saw palmetto until their thyroid function is stable and their surgical team has cleared herbal supplement use. A 2019 American Society of Anesthesiologists consensus statement recommends stopping all herbal supplements 2 weeks before elective procedures. [8]

What the Guidelines Say

No major thyroid guideline from the American Thyroid Association (ATA) or the Endocrine Society specifically addresses saw palmetto combined with liothyronine. The absence of guidance is not the same as a safety endorsement. It reflects the limited clinical trial data on herbal-prescription interactions in thyroid patients generally.

The 2014 ATA and American Association of Clinical Endocrinologists (AACE) hypothyroidism management guidelines do state: "Clinicians should ask patients about use of dietary supplements, as some may impair thyroid hormone absorption or affect thyroid function test interpretation." [9]

The HealthRX clinical team uses a three-question framework when evaluating any supplement added to a liothyronine regimen:

1. Does the supplement alter GI absorption of liothyronine (binding, motility, pH changes)?
2. Does the supplement share pharmacodynamic territory with T3 (coagulation, cardiovascular tone, androgen signaling)?
3. Is the patient's current thyroid status stable, with labs in the last 8 weeks?

Saw palmetto scores low on question 1, moderate on question 2, and question 3 is entirely patient-specific. This pattern suggests a "proceed with monitoring" posture rather than a hard contraindication for most patients.

Monitoring Protocol When Taking Both

If a patient and their clinician decide to continue saw palmetto alongside liothyronine, a structured monitoring approach reduces risk.

Lab Schedule

• Baseline: TSH, free T3, free T4, CBC with platelets, and a brief bleeding-symptom review before adding saw palmetto.
• 6 weeks after initiation: Repeat TSH and free T3. Ask about any new bruising, prolonged bleeding from minor cuts, or urinary symptoms changes.
• Every 3 to 6 months: Routine thyroid panel, consistent with standard liothyronine follow-up intervals recommended by the ATA. [9]

Symptom Checklist

Patients should contact their provider if they notice palpitations, unexplained bruising, nosebleeds lasting more than 10 minutes, unusual fatigue suggesting thyroid-status change, or new urinary symptoms that could indicate prostate changes.

Drug Interaction Databases

The Natural Medicines database rates the saw palmetto and anticoagulant/antiplatelet interaction as "moderate," and flags theoretical thyroid interaction based on the androgen-T3 crosstalk evidence. Mayo Clinic's drug interaction checker lists saw palmetto as having possible interactions with anticoagulants and does not currently list a direct liothyronine flag, which is consistent with the absence of pharmacokinetic evidence. Clinicians should check these databases regularly, as ratings are updated as new data emerge.

Practical Dosing and Timing Guidance

Saw palmetto is studied most at 160 mg of lipophilic extract twice daily or 320 mg once daily. That dose appears in the majority of BPH trials included in the 2012 Cochrane review. [3]

Liothyronine is typically taken on an empty stomach, 30 to 60 minutes before breakfast, to avoid absorption interference from food and other supplements. Saw palmetto, by contrast, is often taken with meals to reduce the mild nausea some users report.

This natural timing difference means most patients are already separating the two by several hours without deliberate effort. Still, a clear written schedule helps compliance and makes interactions easier to track if symptoms arise.

One reasonable protocol:

• 6:00 AM: Liothyronine on an empty stomach
• 7:00 AM: Breakfast
• 8:00 AM: Saw palmetto 160 mg with food (first dose)
• 6:00 PM: Saw palmetto 160 mg with dinner (second dose)

This provides at least 2 hours between liothyronine and saw palmetto, well beyond the window needed to protect absorption.

Alternatives to Saw Palmetto for Patients on Liothyronine

Patients who are concerned about the pharmacodynamic overlap, or whose prescriber prefers to eliminate all potential confounders from their thyroid regimen, have several options.

Finasteride (Propecia 1 mg or Proscar 5 mg): A pharmaceutical 5-AR inhibitor with a well-characterized interaction profile. The drug does not affect thyroid hormone metabolism. The PCPT trial (N=18,882) established its efficacy and safety profile over 7 years. [10]

Dutasteride (Avodart 0.5 mg): Inhibits both 5-AR type 1 and type 2, with stronger DHT suppression than finasteride. No known interaction with liothyronine.

Lifestyle and dietary interventions for BPH symptoms: Reducing caffeine and alcohol, timed fluid intake, and pelvic floor exercises have supporting evidence in mild LUTS management, with zero drug interaction concern.

A Note on Saw Palmetto and Thyroid Function Tests

Several herbal supplements alter thyroid function test results without changing actual thyroid hormone production. Biotin (vitamin B7), for instance, can falsely lower TSH on certain immunoassay platforms at doses above 5 mg daily.

Saw palmetto does not appear to interfere with standard TSH or free T3 immunoassays. No peer-reviewed case report or analytical chemistry study has documented this type of lab interference with Serenoa repens. This is reassuring: a provider interpreting thyroid labs in a patient on both agents does not need to discount or repeat the results on that basis alone.

What to Tell Your Doctor

Patients should bring a complete supplement list to every thyroid follow-up. The conversation about saw palmetto specifically should include:

• The dose and brand being used, since standardization of saw palmetto extracts varies widely between manufacturers.
• The reason for use (BPH symptoms, hair concerns, or general prostate health), which may point toward better-studied pharmaceutical alternatives.
• Any concurrent use of fish oil, vitamin E, aspirin, or NSAIDs, since these create additive antiplatelet burden alongside saw palmetto.
• Planned surgical or dental procedures in the next 3 months.

A physician who knows all of this can make a genuinely individualized recommendation rather than a reflexive "stop the supplement" response.